Ernie Hudson is the new face of Black-men's-cancer screening. Here is the evidence behind starting earlier on three cancers.

The Prostate Cancer Foundation's 2024 Black-men screening guideline recommends baseline PSA testing between ages 40 and 45, ten years earlier than the standard 50-to-55 window for average-risk men, and projects an approximate 30 percent reduction in prostate cancer mortality without substantially increasing overdiagnosis (Garraway et al., NEJM Evidence 2024; PMID 38815168). The 19-author guideline panel reviewed 1,848 publications and built a Black-specific recommendation framework for a population whose age-adjusted prostate cancer mortality is roughly twice the white-male rate.

Ernie Hudson, who has spoken publicly about surviving prostate cancer and later rectal cancer, advocates for cancer prevention awareness in Black communities. The data that explains why the foundation's PSA recommendation moved earlier (and why the 2021 colorectal guideline moved earlier, and why oropharyngeal cancer survival in Black men is the third leg of the framework) is what the rest of this piece is about. Three different cancers, three different evidence-based screening decisions, all pointing toward acting earlier than the white-male population default would suggest.

The Garraway 2024 Prostate Cancer Foundation guideline is the most recent major US screening recommendation specifically built for Black men. Its lead author, Dr. Isla P. Garraway, MD, PhD, is professor of urology at the UCLA David Geffen School of Medicine and chief of urology at the VA Greater Los Angeles Healthcare System. The guideline panel of 19 specialists reviewed 264 relevant publications and issued four core recommendations: Black men should receive structured counseling about PSA screening; baseline PSA testing should occur between ages 40 and 45; annual screening should be considered based on PSA values and health status; screening continues until approximately age 70 (Garraway et al., NEJM Evidence 2024; PMID 38815168).

The 30 percent projected mortality reduction is a guideline-panel projection from underlying screening-efficacy evidence, not a randomized-trial result. Black men were under-represented in the foundational PSA RCTs (ERSPC, PLCO, CAP) the projection draws from, which the guideline acknowledges as a limitation. The Black-specific age threshold rests on observational evidence about earlier-onset disease, more aggressive disease at presentation, and the documented Black-white mortality gap in age-adjusted prostate cancer mortality.

A second piece of evidence reinforces why the Black-specific threshold matters now. A 2026 SEER analysis covering 20 years of US prostate cancer epidemiology found that the 2012 USPSTF Grade D recommendation against routine PSA screening coincided with a 20.6 percent immediate drop in overall prostate cancer incidence and a 9.3 percent rise in metastatic disease at presentation; the paper concluded that "Black men and residents of the Southern U.S. bore the highest burden and the most pronounced temporal shifts" (Jin et al., World Journal of Urology 2026; PMID 41954768). When national screening policy moved against PSA, Black men carried the disease burden the policy reversal created.

Practical reader takeaway. The PCF 2024 guideline applies to you if you are a Black man over 40. The 30 percent projection is an estimate, not a promise; the underlying data on Black-male prostate cancer mortality is the load-bearing fact, and earlier screening is the consensus response.

In 2021, the US Preventive Services Task Force lowered the colorectal cancer screening start age from 50 to 45 for all average-risk adults (Grade B recommendation), citing rising early-onset colorectal cancer and modeling evidence that the lower threshold improves life-years gained at acceptable harm levels (Davidson et al., JAMA 2021; PMID 34003218). The recommendation continues a Grade A recommendation for adults 50 to 75 and a Grade C selective recommendation for adults 76 to 85.

The 2021 update does not contain explicit Black-specific guidance. The accompanying systematic review examined whether findings varied by race or ethnicity; no race-stratified differential recommendation was issued. The age-45 start applies to Black adults the same as it does to white adults. The reason the lower threshold matters more for Black adults is the underlying epidemiology: Black adults present at later stages of colorectal cancer and have higher colorectal cancer mortality. The age-50 starting threshold left a five-year window in which an earlier-onset disease pattern, including patterns that disproportionately affect Black adults, was systematically under-screened.

For Black men specifically, this means three things. Schedule a screening colonoscopy or stool-based test (FIT, FIT-DNA) starting at age 45. If you have a family history of colorectal cancer in a first-degree relative, screening starts earlier (typically age 40 or ten years before the relative's diagnosis age, whichever is younger). The modality choice (colonoscopy vs FIT vs FIT-DNA) is a clinician conversation; the Davidson 2021 recommendation does not stratify modality recommendations by race, and access factors should weigh into the choice.

The third cancer in the screening framework is the one with the least mature consumer-facing guidance. Routine population-level oropharyngeal cancer screening is not currently recommended by USPSTF. What the evidence does show is a substantial Black-male survival deficit.

A nationwide population-based study of 175,843 US males diagnosed with oropharyngeal cancer between 2005 and 2016 found that Black males with HPV-related oropharyngeal cancer had a mean survival of 69.7 months compared with 99.6 months for white males (P less than 0.01), and 78 percent higher cancer-specific mortality after adjustment for treatment factors (adjusted hazard ratio 1.78, 95 percent confidence interval 1.70 to 1.87; Villalona et al., Annals of Family Medicine 2022; PMID 36696662). Adjusting for treatment factors eliminated the higher mortality among Hispanic males but did not eliminate the Black-white mortality gap.

The 30-month difference in mean survival is the single largest race-specific survival gap among the three cancers in this screening framework. The mechanisms are partially understood: Black men have lower HPV-positivity rates in oropharyngeal cancer (and HPV-positive OPCa carries better prognosis), comorbidity differences contribute, treatment access varies, and biological factors may differ. The Villalona paper's adjustment for treatment did not close the gap; specific clinical biology, comorbidity load, and structural access remain partially unexplained drivers.

Practical reader takeaway. Symptom awareness is the lever, since routine screening is not on the table. Persistent sore throat lasting more than two weeks, ear pain on one side, a lump in the neck, or a painless mass at the base of the tongue all warrant ENT evaluation. Routine dental visits should include an oral cancer exam; many do not by default, and asking specifically is reasonable. For adolescents and young adults in the HPV-vaccination age window (9 to 26), vaccination is the upstream prevention move that will eventually lower next-generation oropharyngeal cancer risk.

The framework that links these three cancers is consistent. The Black-male epidemiology supports acting earlier than the population-default screening guidance; for two of the three (prostate via PCF 2024, colorectal via USPSTF 2021) the major US guideline has already moved that way; the third (oropharyngeal) has no routine screening recommendation, and symptom awareness plus dental-exam access cover the gap. Dr. Otis W. Brawley, MD, MACP (Bloomberg Distinguished Professor of Oncology and Epidemiology at Johns Hopkins University and former chief medical and scientific officer of the American Cancer Society) and Dr. Edith P. Mitchell, MD, MACP, FCPP (clinical professor of medicine and medical oncology at the Sidney Kimmel Cancer Center at Jefferson and past president of the National Medical Association) have made the cross-cancer Black-male disparities case in clinical practice and in print for years.

Three concrete actions. The first two are scheduled appointments; the third is a question added to your existing dental routine.

First, if you are a Black man over 40, ask your primary care clinician for a baseline PSA test if you have not had one. Cite the PCF 2024 NEJM Evidence guideline by name. If your clinician defaults to the average-risk-male age-50 start, ask them to follow the Black-specific guidance. Bring family history (any first-degree relative with prostate cancer, especially diagnosed before 65) and ask whether that moves your starting age to 40. The Black Health provider directory lists primary-care clinicians and urologists with verified licenses; our piece on why finding a Black doctor is harder than it should be covers the workforce numbers behind the search.

Second, if you are 45 or older, schedule a colorectal cancer screening: colonoscopy (10-year interval if normal), FIT (annual), or FIT-DNA (every three years) per the USPSTF 2021 recommendation. The choice of modality depends on access, insurance coverage, and personal risk factors; ask your clinician which is the best fit. If you have a family history of colorectal cancer, ask about earlier-than-45 screening.

Third, at your next dental visit, ask for an oral cancer screening exam as part of the visit. Dentists are trained to perform a five-minute visual and tactile exam of the lips, tongue, palate, and tissues at the base of the tongue. Many practices do not perform it by default. If you have noticed a persistent sore throat, ear pain on one side, or a lump in your neck for more than two weeks, ask your primary care clinician for an ENT referral. Our piece on three questions to ask your dentist covers the conversation framework you can adapt for the oral-cancer screening request.

Garraway IP, Carlsson SV, Nyame YA, et al. Prostate Cancer Foundation Screening Guidelines for Black Men in the United States. NEJM Evid 2024;3(5). PMID 38815168. DOI 10.1056/EVIDoa2300289.

Davidson KW, Barry MJ, Mangione CM, et al. Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement. JAMA 2021;325(19):1965 to 1977. PMID 34003218. DOI 10.1001/jama.2021.6238.

Villalona S, Ferrante J, Villalona S, Stroup A. More than cervical cancer: Understanding racial/ethnic disparities in oropharyngeal cancer outcomes among males by HPV status. Ann Fam Med 2022;20(Suppl 1):2625. PMID 36696662. DOI 10.1370/afm.20.s1.2625.

Jin S, et al. Screening policy changes and prostate cancer epidemiology: 20-year trends in diagnosis, treatment, incidence, and mortality. World J Urol 2026. PMID 41954768. DOI 10.1007/s00345-026-06277-5.

Malik Johnson is a senior staff writer covering Black health. Send tips to our contact form.